Sun Pharma Gets CDSCO Panel Nod for Active PMS of Fexuprazan Hydrochloride Tablets
New Delhi: Sun Pharma Laboratories has got the go-ahead from the Subject Expert Committee (SEC) functioning under the Central Drugs Standard Control Organization (CDSCO) for conducting an active post-marketing surveillance (PMS) study of Fexuprazan hydrochloride tablets 40 mg.
This came after the firm presented the active PMS study protocol for the drug Fexuprazan hydrochloride tablets 40 mg before the committee in light of earlier SEC recommendations dated 12.12.2024 and as per condition no. 9 of the new drug permission for Fexuprazan hydrochloride tablets 40 mg.
Fexuprazan Hydrochloride is used for the treatment of acid-related gastrointestinal disorders, and the PMS study will monitor its safety and efficacy in real-world clinical use.
Fexuprazan is a drug for the treatment of gastroesophageal reflux disease (GERD).It is a potassium-competitive acid blocker, which is a class of drugs that suppresses gastric acids.
Fexuprazan has a fast onset of action and stable suppression of gastric acid. It can be taken regardless of food intake. Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers (P-CABs), implying a longer duration of acid suppression, which helps to achieve optimal nocturnal symptom control.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.